We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+1.24%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.93B
AUM Growth
-$191M
Cap. Flow
-$51.4M
Cap. Flow %
-1.75%
Top 10 Hldgs %
43.92%
Holding
115
New
17
Increased
19
Reduced
24
Closed
19

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$145M
2
IMTX icon
Immatics
IMTX
+$43.5M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$38.6M
4
KO icon
Coca-Cola
KO
+$35.8M
5
CZR icon
Caesars Entertainment
CZR
+$30.6M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$78.3M
2
ACLX
Arcellx
ACLX
+$57.6M
3
RPRX icon
Royalty Pharma
RPRX
+$52.8M
4
T icon
AT&T
T
+$50.3M
5
UNH icon
UnitedHealth
UNH
+$40.7M

Sector Composition

Rank Sector Weight
1 Healthcare 55.9%
2 Consumer Discretionary 8.93%
3 Technology 8.81%
4 Financials 5.59%
5 Communication Services 4.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
51
Sutro Biopharma
STRO
$421M
$13.7M 0.47%
746,250
+27,500
+4% +$840K
CRWD icon
52
CrowdStrike
CRWD
$218B
$12.3M 0.42%
144,372
-344,248
-70% -$28.6M
ZURA icon
53
Zura Bio
ZURA
$566M
$12.2M 0.41%
4,860,939
– –
GLUE icon
54
Monte Rosa Therapeutics
GLUE
$1.35B
$10.9M 0.37%
1,563,798
-1,095,202
-41% -$8.22M
MOLN
55
Molecular Partners
MOLN
$10.5M 0.36%
2,221,494
+1,821,494
+455% +$10M
DIS icon
56
Walt Disney
DIS
$181B
$10.5M 0.36%
+94,580
New +$9.94M
RCUS icon
57
Arcus Biosciences
RCUS
$3.64B
$8.58M 0.29%
576,156
-87,447
-13% -$1.43M
PVLA
58
Palvella Therapeutics
PVLA
$2.27B
$8.57M 0.29%
+714,463
New +$11.2M
BIOA
59
BioAge Labs
BIOA
$538M
$8.41M 0.29%
1,452,336
-2,664
-0.2% -$45.9K
SCPH
60
DELISTED
scPharmaceuticals
SCPH
$6.52M 0.22%
1,840,891
-208,118
-10% -$797K
SNY icon
61
Sanofi
SNY
$104B
$6.34M 0.22%
131,501
-43,400
-25% -$2.21M
GEHC icon
62
GE HealthCare
GEHC
$32.4B
$5.86M 0.2%
75,000
– –
EXAS
63
DELISTED
Exact Sciences
EXAS
$5.29M 0.18%
94,100
– –
MRK icon
64
Merck
MRK
$318B
$5.27M 0.18%
+53,000
New +$5.46M
KZR
65
DELISTED
Kezar Life Sciences
KZR
$4.82M 0.16%
716,759
– –
PEPG icon
66
PepGen
PEPG
$197M
$4.45M 0.15%
1,174,321
-486,611
-29% -$3.03M
TMO icon
67
Thermo Fisher Scientific
TMO
$220B
$4.11M 0.14%
7,900
+640
+9% +$352K
ABT icon
68
Abbott
ABT
$187B
$3.79M 0.13%
33,520
– –
DHR icon
69
Danaher
DHR
$144B
$3.12M 0.11%
13,600
-2,827
-17% -$695K
ELAN icon
70
Elanco Animal Health
ELAN
$11.1B
$3.07M 0.1%
253,600
– –
COR icon
71
Cencora
COR
$61.2B
$2.81M 0.1%
12,488
– –
ISRG icon
72
Intuitive Surgical
ISRG
$134B
$2.71M 0.09%
5,200
– –
DXCM icon
73
DexCom
DXCM
$32B
$2.46M 0.08%
31,680
– –
MTD icon
74
Mettler-Toledo International
MTD
$28.6B
$2.4M 0.08%
1,964
– –
SRPT icon
75
Sarepta Therapeutics
SRPT
$1.77B
$2.18M 0.07%
+17,888
New +$2.19M
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Suvretta Capital Management held 115 positions worth $2.93B, down 6.1% from $3.13B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Suvretta Capital Management's Q4 2024 filing shows 17 new, 19 increased, 24 reduced and 19 closed positions. Its largest new stake was Legend Biotech: 3,496,234 shares worth $114M. The largest sale was Apple, an estimated $78.3M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 53% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Suvretta Capital Management's largest Q4 2024 buy was Legend Biotech: 3,496,234 shares worth $114M.
  • Suvretta Capital Management added most to Coca-Cola in Q4 2024, an estimated $35.8M increase.
  • Suvretta Capital Management's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $40.7M.
  • Suvretta Capital Management fully exited Apple in Q4 2024, selling an estimated $78.3M.
  • Suvretta Capital Management's ten largest holdings make up 44% of its $2.93B portfolio in Q4 2024.
  • Suvretta Capital Management opened 17 new positions and closed 19 in Q4 2024.
  • Suvretta Capital Management's portfolio value fell 6.1% quarter-over-quarter to $2.93B.

Based on Suvretta Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.